Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

Abroad (travel likely)RecruitingPHASE2

Conditions

Autism Spectrum Disorder · Anxiety

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
Contact: Study coordinator (Christopher J Smith, Ph.D.) · csmith@autismcenter.org · 602-218-8192
Contact: Study coordinator (Brian Shaw) · bshaw@autismcenter.org · 602-340-8717
Contact: Principal Investigator (Christopher J Smith, Ph.D.)

Study leads

Christopher J Smith, Ph.D.
Principal Investigator
SARRC

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th

Autism Spectrum Disorders

Abroad (travel likely)RecruitingPHASE3

Paris, France · Barcelona, Spain

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

Autism Spectrum Disorder · ASD

Abroad (travel likely)RecruitingPHASE2

New York, United States

The Impact of a Virtual Magic Trick Training Program

Autism · Pervasive Developmental Disorder

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States

Auricular Transcutaneous Electrical Nerve Stimulation Treatment of Autism

Autism Spectrum Disorder

Abroad (travel likely)Recruiting

Charlestown, United States